We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Patent Board Sides With Novo Nordisk on Semaglutide Challenge From Generic Maker Viatris
Patent Board Sides With Novo Nordisk on Semaglutide Challenge From Generic Maker Viatris
On Monday the U.S. Patent and Trial and Appeal Board (PTAB) ruled that Novo Nordisk, maker of semaglutide, did not choose the “obvious” research road drug, thereby denying Mylan Pharmaceuticals its challenge on two of Novo’s existing patents.
